AURA - BTIG initiates Aura Biosciences with a buy on targeted oncology approach

BTIG has initiated Aura Biosciences (NASDAQ:AURA) with a buy rating citing the company's novel targeted oncology platform. The firm has a $38 price target (~112% upside). Analyst Bert Hazlett speaks highly of Aura's lead candidate AU-011 (belzupacap sarotalocan), a virus-like drug conjugate in phase 2 for chorodial melanoma, the most common type of intraocular cancer. He says the double target of AU-011 "has the potential to preserve key eye structures and patients' vision, providing the potential for adoption in early-stage disease." Hazlett adds that the dual mechanism of action can provide tumor control and durable response. Aura has its IPO late last month.

For further details see:

BTIG initiates Aura Biosciences with a buy on targeted oncology approach